Sixteen healthy young volunteers (seven females, nine males) received repeated doses of either 30 mg paroxetine, 100 mg maprotiline or placebo in a double-blind crossover study. Each of the three treatments lasted 1 week separated by 2 weeks of no treatment. Treatment order was counterbalanced. Subjects were tested before each treatment period, and after 1 and 7 days of treatment. Measurements were made of mood, perceptual-motor skills, and eye movements including pupil size when subjects were watching a traffic film.
Get full access to this article
View all access options for this article.
References
1.
Blackwell B., Simon J.S.1986Second-generation antidepressantsDrugs of Today22(12): 611-633
2.
Buus Lassen J.1978Potent and long-lasting potentiating of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitorsEuropean Journal of Pharmacology47: 351-358
3.
Cooper S.M., Jackson D., Loudon J.M., McClelland G.R., Raptopoulos P.1988The psychomotor effects of paroxetine alone and in combination with oxazepam, amylobarbitone and haloperidolExtended abstracts and poster presentations of the paroxetine symposium, Rome, October 1988
4.
Dunbar G.C.1988An interim overview of the safety and tolerability of paroxetineExtended abstracts and poster presentations of the paroxetme symposium, Rome, October 1988
5.
Guy Edwards J., Sedgwick E.M., Punter J., Goldie A., Papayanm-Papasthatis S.1988Extended abstracts and poster presentations of the paroxetine symposium, Rome, October, 1988
6.
Hindmarch I., Harrison C.1988The effects of paroxetine and other antidepressants in combination with alcohol in psychomotor activity related to car drivingHuman Psychopharmacology3: 13-20
7.
Halmi K.A., Ackerman S., Gibbs J., Smith G.1978Basic biological overview of the eating disorders. In Psychopharmacology, the third generation of progress (eds Meltzer H Y) 1255-1266
8.
Janke W, Debus G 1978 List of adjectives. The PC/S Vienna Test System. Dr. G. Schuhfried Ges.m.b.H., Mödling, Austria: 36-37.
9.
Klemenjak W.1983Das Wiener Konzentrationsgerat (cognitrone). Neue Methoden der apparativen Erfassung kognitieven LeistungenKuratorium für Verkehrssicherheit, Wien
10.
Lund Laursen A., Mikkelsen P.L., Rasmussen S., Le Fevre Honore P.1985Paroxetine in the treatment of depression-a randomized comparison with amitriptylineActa Psychiatrica Scandinavica71(3): 249-255
11.
Mackworth N.H.1950Researches on the measurement of human performance Medical Research Council Special Report No 268. London, HMSO
12.
Moro F., Scapagnini U., Scaletta S., Drago F.1981Serotonin nerve endings and regulation of pupillary diameterAnnals of Ophthalmology13: 487-490
13.
Petersen E.N., Bechgaard E., Sortwell R.J., Wetterberg L.1978Potent depletion of 5HT from monkey whole blood by a new 5HT uptake inhibitor, paroxetineEuropean Journal of Pharmacology52: 115-119
14.
Pouw E F M(In press). Het determinatietoestel, analyse van de reactietijden In Selectie research in de praktijk (eds H. v.d. Flier, P G W Janssen, J N Zaal)
15.
Raptopoulos P., McClelland G.R., Jackson D.1988The clinical pharmacology of paroxetine in healthy subjectsExtended abstracts and poster presentations of the paroxetine symposium, Rome, October 1988
16.
Robinson D.S.1984Adverse reactions, toxicities, and drug interactions of newer antidepressants: anticholinergic, sedative and other side effectsPsychopharmacology Bulletin20(2): 280-290
17.
Tyrer P., Marsden C.A., Casey P., Seivewright N.1988Clinical effects of paroxetine in resistant depressionExtended abstracts and poster presentations of the paroxetine symposium, Rome, October 1988
18.
Warrington S., Haeri J.D., Sinclair A.J.1988Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy menExtended abstracts and poster presentations of the paroxetine symposium, Rome, October 1988
